BUB
SUPN icon

BBVA USA Bancshares’s Supernus Pharmaceuticals SUPN Stock Holding History

BBVA USA Bancshares’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$216K Sell
8,257
-696
-8% -$19.5K 0.01% 522
2020
Q4 		$225K Sell
8,953
-2,181
-20% -$46.9K 0.01% 506
2020
Q3 		$232K Sell
11,134
-827
-7% -$18.8K 0.01% 480
2020
Q2 		$284K Buy
+11,961
New +$264K 0.02% 453

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

BBVA USA Bancshares's SUPN Position: Q1 2021 in Review

BBVA USA Bancshares reduced its Supernus Pharmaceuticals (SUPN) stake by 7.8% in Q1 2021, selling an estimated $19.5K and leaving 8,257 shares worth $216K. The position accounts for 0.01% of the portfolio, ranked #522.

BBVA USA Bancshares first reported a position in SUPN in Q2 2020 and has held it in 4 quarters since. The position peaked at $284K in Q2 2020. 224 funds tracked by Wall St. Rank hold SUPN as of Q1 2021.

  • BBVA USA Bancshares held 8,257 shares of Supernus Pharmaceuticals worth $216K as of Q1 2021.
  • BBVA USA Bancshares sold 696 Supernus Pharmaceuticals shares in Q1 2021, an estimated $19.5K.
  • Supernus Pharmaceuticals made up 0.01% of BBVA USA Bancshares's portfolio in Q1 2021, its #522 holding.
  • BBVA USA Bancshares first reported a position in Supernus Pharmaceuticals in Q2 2020 and has held it in 4 quarters since.
  • BBVA USA Bancshares's Supernus Pharmaceuticals position peaked at $284K in Q2 2020.
  • 224 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2021.

Based on BBVA USA Bancshares's 13F filing for Q1 2021, filed 23 Apr 2021.